Sponsors (7)
The bill strengthens biosafety, traceability, and federal coordination to prevent and respond to dangerous biological transfers and lab incidents, but does so by centralizing sensitive data and imposing new compliance requirements that raise costs, privacy/security concerns, and reduce public transparency.
State, local, Tribal public‑health officials and researchers get faster detection and response to unsafe transfers and lab incidents because covered transfers must be logged electronically and authorized officials can access logbook data, there is a single federal point of contact, and a feasibility study/database and national standards will improve situational awareness.
Scientists, covered distributors, and hospitals gain stronger traceability and accountability for transfers because standardized electronic recordkeeping and identity verification (IDs/signatures) deter diversion and illicit acquisition of high‑risk agents.
Sensitive biosurveillance and transfer data are better protected from public disclosure because the bill limits disclosure and creates FOIA exemptions for specified records, reducing the risk that information about high‑risk agents is misused.
Covered distributors, biobanks, lab owners, and research institutions will face increased compliance and administrative costs to implement Secretary‑specified electronic logbooks and to meet new national standards and oversight requirements.
Researchers, purchasers, and facility owners will face privacy and legal‑risk concerns because the bill requires detailed personal/business information for transfers, may impose criminal penalties for false statements, and contemplates collecting owner identities and locations.
Broad FOIA exemptions and restricted access to transfer/location data reduce transparency and public oversight, limiting accountability for how the program and labs are managed.
Based on analysis of 3 sections of legislative text.
Mandates electronic logbooks for transfers of defined highly pathogenic agents, requires HHS to publish an agent list, and creates federal oversight and periodic evaluations of BSL‑3+ labs.
Official title: To require the Secretary of Health and Human Services, acting through the Assistant Secretary for Preparedness and Response, to carry out a program under which the Secretary requires each covered distributor of a highly pathogenic agent to comply with certain logbook requirements, and for other purposes.
Introduced October 14, 2025 by Jim Costa · Last progress October 14, 2025
Requires federal tracking of transfers of defined “highly pathogenic agents” by covered distributors through Secretary‑specified electronic logbooks, with required purchaser verification, retention, and strict disclosure limits; directs HHS/ASPR to publish and annually update the list of covered agents. Directs the National Security Advisor to designate a single federal entity to perform periodic strategic evaluations of all high‑containment (BSL‑3+) laboratories, produce national design/operations standards, create a Public Health Biosafety and Biosecurity Team as a central contact for subnational authorities, and study the feasibility of a public database of facility information.